BESREMi

Amarin Highlights New REDUCE-IT Data at ESC 2026

DUBLIN and BRIDGEWATER, N.J., August 31, 2026 Amarin Corporation plc highlighted new findings from multiple REDUCE-IT® analyses presented at...

By cGxPwire Editor
September 1, 2026

Bio-Pharma

PharmaEssentia Wins FDA Approval for BESREMi in ET

BURLINGTON, Mass., August 31, 2026 PharmaEssentia announced that the U.S. Food and Drug Administration (FDA) has approved BESREMi® (ropeginterferon...

By cGxPwire Editor
September 1, 2026

Pharma

PharmaEssentia Wins Canadian Approval for BESREMi in Rare Blood Cancer

BURLINGTON, Mass., July 6, 2026 PharmaEssentia Corporation announced that its wholly owned Canadian subsidiary, FORUS Therapeutics Inc., has received...